Graypoint LLC Purchases 75 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Graypoint LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,262 shares of the medical research company’s stock after acquiring an additional 75 shares during the period. Graypoint LLC’s holdings in IQVIA were worth $299,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. GSA Capital Partners LLP acquired a new position in IQVIA in the 1st quarter worth $700,000. Empowered Funds LLC boosted its holdings in IQVIA by 35.5% in the 1st quarter. Empowered Funds LLC now owns 2,512 shares of the medical research company’s stock valued at $635,000 after purchasing an additional 658 shares during the period. Sei Investments Co. grew its position in shares of IQVIA by 4.8% during the 1st quarter. Sei Investments Co. now owns 57,887 shares of the medical research company’s stock worth $14,638,000 after purchasing an additional 2,638 shares in the last quarter. NorthRock Partners LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $233,000. Finally, Meeder Advisory Services Inc. increased its stake in IQVIA by 5.7% during the 1st quarter. Meeder Advisory Services Inc. now owns 3,148 shares of the medical research company’s stock worth $796,000 after acquiring an additional 169 shares during the period. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on IQV. Morgan Stanley reduced their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $259.13.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Up 0.7 %

IQVIA stock opened at $219.23 on Friday. The firm has a market capitalization of $39.79 billion, a price-to-earnings ratio of 28.77, a P/E/G ratio of 2.26 and a beta of 1.51. IQVIA Holdings Inc. has a 1-year low of $190.20 and a 1-year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a 50 day simple moving average of $231.00 and a 200 day simple moving average of $229.31.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.